We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Cell and Tissue Acquisition Device Improves Efficiency at More Affordable Price

By LabMedica International staff writers
Posted on 26 Feb 2013
An innovative and affordable new cell and tissue acquisition instrument improves efficiency and ease-of-use compared to existing laser-assisted microdissection systems.

Kuiqpick, introduced by NeuroInDx, Inc. More...
(Los Angeles, CA, USA), is the innovative new laser-assisted microdissection and acquisition system for research laboratories. It includes the additional the capacity to collect cells from tissues and cultures without affecting their viability, enabling the collected cells to then be cultured for further analysis and downstream applications. Also notable, Kuiqpick costs less than USD 30,000 per device, about one-fourth the cost of existing systems. “Kuiqpick [opens] the door for more labs to conduct the critical collection of live cells and tissue areas for examination and culturing,” said Stan Karsten, PhD, NeuroInDx chief scientific officer and cofounder; “For too long, the high cost of tissue microdissection and cell sorting technologies have limited cell-specific research. With the introduction of Kuiqpick, more labs and researchers can afford the technology.”

Rebecca Stockton, PhD, a University of California, Los Angeles (UCLA) assistant professor of pediatrics, uses Kuiqpick to study cerebral cavernous malformations and said, “[Kuiqpick is] perfect for collecting small abnormal blood vessels from the brain tissue and specific cells from cultures based on their form and structure, or their morphology, which is critical for my research.”

Originally conceived at UCLA and further developed by NeuroInDx, Kuiqpick can be attached to an inverted microscope to dissect brain tissue slices at the cellular resolution and collect individual cells from various cell cultures. A single press of a button initiates the collection of the brain tissue area or cells into a disposable capillary unit. Collected tissue samples are then transferred to a test tube for further use. “Kuiqpick is a novel and highly accurate system that has already proven to be extremely efficient in the isolation of specific cell populations from live and freshly frozen brain tissues,” said Dr. Lili C. Kudo, president and CEO of NeuroInDx; “It can be successfully used in a variety of molecular studies, including stem cell research, genomics and proteomics.”

NeuroInDx also offers to provide researchers with custom cell and tissue collection services and subsequent gene expression-microarray experiments, thus saving time and funding for their projects.

Related Links:

NeuroInDx





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.